Moderna Inc. ($MRNA) Stock Forecast: Down 7.7% Today

What is Moderna Inc.?

A biotechnology company, Moderna (MRNA) is renowned for its mRNA technology, notably in the field of vaccine development. The stock showed a bearish trend today amidst a generally optimistic market sentiment in the healthcare industry.

Why is Moderna Inc. going down?

MRNA stock is down 7.7% on May 11, 2026 18:41

• Despite a 6% surge earlier, Moderna's stock faced a bearish movement, potentially influenced by profit-taking following recent positive momentum.
• Initially boosted by renewed interest in Moderna's Hantavirus vaccine due to an outbreak, concerns about normalizing COVID-era revenue and GAAP losses may have contributed to the downturn.
• Investors seem to exercise caution due to uncertainties surrounding the revenue potential of the broader mRNA platform and the company's ability to sustain competitiveness against peers like Pfizer and Novavax in the vaccine sector.
• While the market sentiment towards Moderna remains positive, driven by upcoming Phase 3 readouts and a diverse pipeline, short-term volatility could linger as investors navigate challenges tied to the pandemic.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Does the Recent Hantavirus Outbreak Highlight a Critical Gap for NanoViricides' NV-387

The recent Andes hantavirus outbreak on the MV Hondius underscores a critical need for broad-spectrum antiviral treatments, a gap NanoViricides' NV-387 aims to fill. NV-387, employing a novel "Re-Infection Inhibition" mechanism, has shown promise in Phase I trials and animal models against multiple viruses. While NanoViricides faces financial challenges as a pre-revenue company, strategic regulatory pathways like Orphan Drug Designation and non-dilutive government funding could accelerate its path to market and provide significant upside for long-term, high-risk tolerant investors.

https://www.kavout.com/market-lens/does-the-recent-hantavirus-outbreak-highlight-a-critical-gap-for-nanoviricides-nv-387

Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Moderna (MRNA) stock surged 6% today, outperforming Pfizer (PFE) and Novavax (NVAX), driven by renewed interest in its Hantavirus vaccine following a cruise ship outbreak and a strong Q1 2026 revenue beat. While Hantavirus demand may be limited, Moderna's broader mRNA platform for flu, RSV, oncology, and rare diseases, along with upcoming Phase 3 readouts, support its bullish momentum. However, concerns remain about normalizing COVID-era revenue and GAAP losses, suggesting a cautious approach for investors.

https://247wallst.com/investing/2026/05/11/moderna-stock-is-up-6-today-is-it-outperforming-other-vaccine-stocks-like-pfizer-and-novavax/

Thermo Fisher Sci. stock (US8835561023): Leader in life sciences tools

Thermo Fisher Scientific is a leading company in the life sciences and diagnostics sector, offering essential instruments and consumables for research labs, pharma, and biotech. The company operates through four main segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services, focusing on diverse scientific research and industrial applications. With strong market share, strategic acquisitions, and a significant portion of its revenue from North America, Thermo Fisher Sci. is considered a cornerstone in life sciences, appealing to long-term equity holders despite biotech funding volatility.

https://www.ad-hoc-news.de/boerse/news/ueberblick/thermo-fisher-sci-stock-us8835561023-leader-in-life-sciences-tools/69306393

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Iovance Biotherapeutics (NASDAQ:IOVA) missed its first-quarter earnings, reporting revenues of US$71m, which was 5.6% below analyst predictions, and a larger-than-expected statutory loss of US$0.19 per share. Despite maintaining revenue forecasts for 2026 at US$365.8m, analysts increased their per-share loss expectations to US$0.55. The consensus price target remained at US$8.80, suggesting analysts believe the company's intrinsic value is stable despite the higher projected losses.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/iovance-biotherapeutics-inc-nasdaqiova-first-quarter-results

Nanobiotix Shares Set a New Record at €41.52, Up 1,202% Over the Year

Nanobiotix shares reached a new all-time high of €41.52, marking a 1,202% increase over the year and making it the second-highest gainer on the SBF 120. This surge follows the FDA's approval of an amendment to its NANORAY-312 Phase 3 study protocol. The stock's technical indicators show significant upward momentum, trading well above its moving averages and signaling an overbought condition.

https://www.ideal-investisseur.fr/en/actions-b/nanobiotix-shares-set-a-new-record-at-eur41-52-up-1-202-over-the-year/19024.html

Trending Today

Perrigo Company plc ($PRGO) Stock Forecast: Down 5.0% Today

CF Industries Holdings Inc. ($CF) Stock Forecast: Up 5.6% Today

Airbnb Inc. ($ABNB) Stock Forecast: Down 5.1% Today

AMC Entertainment Holdings Inc. Class A ($AMC) Stock Forecast: Down 5.2% Today

Zebra Technologies Corporation ($ZBRA) Stock Forecast: Down 5.1% Today

Trimble Inc. ($TRMB) Stock Forecast: Down 5.1% Today

Booking Holdings Inc. ($BKNG) Stock Forecast: Down 5.0% Today

Zoetis Inc. Class A ($ZTS) Stock Forecast: Down 5.3% Today

Amplitude Inc. ($AMPL) Stock Forecast: Down 5.1% Today

Excelerate Energy ($EE) Stock Forecast: Up 5.1% Today

Moderna Inc. Price History

07.04.2026 - MRNA Stock was up 8.5%

• The surge in Moderna's stock is likely linked to positive updates regarding its mRNA-1010 candidate for seasonal influenza, which displayed superior efficacy in Phase 3 trials compared to traditional flu vaccines.
• The announcement of the vaccine's robust relative efficacy, particularly in adults over 65 and overall, against different influenza strains, likely bolstered investor faith in Moderna's vaccine portfolio.
• The anticipation surrounding the potential FDA verdict on the vaccine by August 5, 2026, coupled with ongoing evaluations by regulatory bodies in various nations, contributed to the optimistic outlook on Moderna's influenza vaccine, fueling the stock's bullish movement.

06.04.2026 - MRNA Stock was up 5.3%

• Moderna (MRNA) stock showed a strong bullish trend today, despite posting a quarterly revenue of $389 million and a GAAP net loss of $1.34 billion, both higher than the previous year.
• The upturn in the stock could be due to an analyst reiterating a Buy rating on Moderna with a price target of $69.00, signaling optimism and growth potential for the company.
• Market participants may be hopeful about Moderna's future performance, given the advancements in the healthcare sector and the company's ongoing work in vaccine research and development.
• The positive market sentiment towards healthcare and the recommendation from the analyst likely contributed to the stock's bullish movement today.

01.04.2026 - MRNA Stock was down 5.1%

• Moderna posted robust Q1 revenue, fueled by strong international sales of COVID-19 vaccines, although it incurred a substantial net loss mainly attributed to a $950 million settlement for a patent dispute.
• Despite surpassing revenue projections and showcasing progress in its pipeline, the market responded negatively to the company's increased net loss and negative gross margins stemming from the litigation charge.
• Observers are closely monitoring Moderna's pipeline advancements, notably the forthcoming FDA verdict on the mRNA-1010 flu vaccine and advanced oncology trials, as these factors impact the stock's premium valuation despite uncertainties regarding profitability.
• Market sentiment towards Moderna appears to be swayed by the company's financial results, legal challenges, and the critical role of its pipeline in determining its future prospects.

01.04.2026 - MRNA Stock was down 5.2%

• Strong Q1 2026 financial results were reported by Moderna, with significant revenue growth driven by higher international sales of its COVID-19 vaccine. Despite this positive development, the stock witnessed a bearish movement, potentially linked to profit-taking after a period of strong performance.
• The company's GAAP net loss, attributed to a non-recurring litigation settlement charge, may have also contributed to investor concerns despite the revenue beat.
• Moderna's stock price surge in premarket trading and after-market hours suggests that investors initially reacted positively to the earnings report, but the bearish movement during the trading day indicates a shift in sentiment.
• The reaffirmed growth outlook and expansion into new product approvals demonstrate Moderna's commitment to innovation and long-term growth, which could potentially attract investors back to the stock in the future.

08.04.2026 - MRNA Stock was up 12.8%

• Following the release of positive Phase 3 flu vaccine data, Moderna's stock showed a strong bullish trend. The data highlighted the efficacy of mRNA-1010 compared to standard flu vaccines in older adults.
• Moderna's stock rebounded after favorable earnings and a successful performance in 2026. This reflected investor confidence in the company's mRNA platform and its potential for revenue growth beyond the realm of COVID-19 vaccines.
• The positive Phase 1 data announcement for Moderna's mRNA hantavirus vaccine further boosted investor confidence. This demonstrated how Moderna's mRNA technology can effectively target different viral diseases.
• Moderna's recent bullish market movement can be linked to its successful vaccine developments, robust earnings, and the confirmation of its mRNA platform's potential to address a broad array of health issues.

08.04.2026 - MRNA Stock was up 6.2%

• The strong bullish movement of Moderna's stock today is due to the positive Phase 1 data release for its mRNA hantavirus vaccine, showcasing its versatility in targeting different viral diseases and renewing investor confidence in the company's mRNA pipeline.
• Moderna's shares rebounded following positive quarterly earnings and a strong 2026 performance, with investors considering the transition from pandemic-driven revenues to a broader product portfolio.
• Investor sentiment received a boost as Gateway Investment Advisers LLC significantly increased its stake in Moderna, especially with promising Phase 3 results for the company's seasonal flu vaccine, mRNA-1010.
• Market sentiment towards Moderna was positive despite developments from other biotech companies like CytomX Therapeutics and Arrowhead Pharmaceuticals, underscoring the market's focus on specific companies' developments and performance.

08.04.2026 - MRNA Stock was up 13.7%

• Moderna's bullish movement can be attributed to the positive Phase 3 flu vaccine data for its mRNA-1010 candidate, showcasing superior efficacy compared to standard flu vaccines.
• The SEC filing indicating a proposed sale of securities might have initially caused some uncertainty but was overshadowed by the promising vaccine results.
• The positive news from Regeneron Pharmaceuticals receiving FDA approval for the first neurosensory gene therapy could have boosted overall investor sentiment in the biotech sector, benefiting Moderna as well.
• Moderna's potential for building durable revenue beyond COVID-19 vaccines with upcoming FDA approvals could have further fueled investor optimism, driving the stock's bullish momentum.

08.04.2026 - MRNA Stock was up 11.8%

• Ongoing research into hantavirus vaccines by Moderna may have boosted investor confidence in the company's ability to address emerging infectious diseases, contributing to the bullish movement.
• A SEC filing indicating a proposed sale of securities by Moderna may have initially caused some uncertainty among investors, but the overall positive sentiment surrounding the company's vaccine development efforts likely overshadowed this news.
• The broader positive sentiment in the biotechnology sector, as evidenced by Cboe Global Markets hitting an all-time high, could have also positively influenced Moderna's stock performance today.
• Moderna's focus on advancing its vaccine pipeline, as seen in the update on its RSV and H5 flu vaccine trial, may have further reinforced investor optimism in the company's long-term growth prospects, contributing to the bullish market movement.

07.04.2026 - MRNA Stock was down 6.1%

• The stock of Moderna faced a downward trend today despite the positive developments related to its mRNA technology and vaccine progress.
• Following the release of robust Q1 outcomes and promising data on its COVID vaccine, Novavax's stock saw a significant increase, potentially shifting investor focus away from Moderna.
• Concerns arose within the biotech sector after the Phase 3 trial failure of Lipocine's LPCN 1154 for postpartum depression, impacting Moderna's stock.
• Internal disagreements at the FDA, exemplified by Sanofi requesting the removal of Tzield from the CNPV program, might have instigated uncertainty over regulatory procedures for companies like Moderna, influencing the downward movement.

11.04.2026 - MRNA Stock was down 7.7%

• Despite a 6% surge earlier, Moderna's stock faced a bearish movement, potentially influenced by profit-taking following recent positive momentum.
• Initially boosted by renewed interest in Moderna's Hantavirus vaccine due to an outbreak, concerns about normalizing COVID-era revenue and GAAP losses may have contributed to the downturn.
• Investors seem to exercise caution due to uncertainties surrounding the revenue potential of the broader mRNA platform and the company's ability to sustain competitiveness against peers like Pfizer and Novavax in the vaccine sector.
• While the market sentiment towards Moderna remains positive, driven by upcoming Phase 3 readouts and a diverse pipeline, short-term volatility could linger as investors navigate challenges tied to the pandemic.

11.04.2026 - MRNA Stock was down 5.1%

• Moderna's stock increased by 6% today, surpassing other vaccine companies like Pfizer and Novavax. This was driven by heightened interest in its Hantavirus vaccine after a recent outbreak on a cruise ship and robust Q1 2026 revenue results. However, concerns about returning to pre-COVID revenue levels and ongoing losses might have led to profit-taking and a bearish trend in the stock.
• Moderna's wide-ranging mRNA platform, along with upcoming Phase 3 study outcomes, continues to support its positive market momentum despite the recent decline.
• The overall market sentiment towards biotech companies and uncertainties about future revenue sustainability post-COVID may have played a role in today's downward movement for Moderna's stock.
• Investors are likely approaching Moderna's stock with caution due to uncertainties surrounding its revenue sources and future profitability.

06.04.2026 - MRNA Stock was up 5.0%

• Moderna (MRNA) witnessed a notable surge in its stock price today, which could potentially be attributed to the following factors:
• A reiterated Buy rating by Piper Sandler analyst Edward Tenthoff with a price target of $69.00, reflecting confidence in the company's future prospects.
• Notwithstanding the disclosure of a quarterly revenue amounting to $389 million and a substantial GAAP net loss, the upbeat analyst sentiment and growth potential might have uplifted investor confidence.
• The prevailing positive sentiment towards biopharmaceutical firms in the market, apparent from the achievements and favorable developments of other companies like Edgewise Therapeutics and Cellectar Biosciences, could have also influenced Moderna's upward movement.
• Investors could be placing greater emphasis on the long-term promise of Moderna's mRNA technology and its pivotal role in shaping forthcoming vaccines and therapeutics, rather than solely focusing on near-term financial indicators.